News
XOMA
26.46
+1.11%
0.29
Weekly Report: what happened at XOMA last week (0630-0704)?
Weekly Report · 1d ago
Collect Up To 11.5% From The Healthcare Sector
Seeking Alpha · 2d ago
CIO Makes Bold Investment Move in Xoma Stock!
TipRanks · 6d ago
Weekly Report: what happened at XOMA last week (0623-0627)?
Weekly Report · 06/30 11:34
Morning Movers: Li Auto lower following Q2 delivery guidance cut
TipRanks · 06/27 13:01
XOMA Royalty To Acquire Turnstone Biologics
NASDAQ · 06/27 12:13
Turnstone Biologics to be acquired by XOMA Royalty
Seeking Alpha · 06/27 12:00
XOMA Royalty to Buy Turnstone Biologics
Dow Jones · 06/27 11:56
Xoma to acquire Turnstone Biologics for $0.34 in cash per share
TipRanks · 06/27 11:40
*XOMA Royalty: Merger Transaction Is Expected to Close in August >XOMA
Dow Jones · 06/27 11:31
TURNSTONE BIOLOGICS CORP - DEAL VALUED AT $0.34 PER SHARE PLUS CVR
Reuters · 06/27 11:30
Press Release: Turnstone Biologics Corp. Enters -2-
Dow Jones · 06/27 11:30
*XOMA Royalty Will Acquire Turnstone Biologics for $0.34 in Cash Per Turnstone Common Shr Plus One Non-Transferable Contingent Value Right >XOMA
Dow Jones · 06/27 11:30
Press Release: Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right
Dow Jones · 06/27 11:30
XOMA Royalty (XOMA) Moves 9.0% Higher: Will This Strength Last?
NASDAQ · 06/24 14:38
Weekly Report: what happened at XOMA last week (0616-0620)?
Weekly Report · 06/23 11:26
XOMA Royalty Corporation Announces Cash Dividends for Series A and Series B Preferred Stock
NASDAQ · 06/18 11:42
Press Release: XOMA Royalty Declares Quarterly Preferred Stock Dividends
Dow Jones · 06/18 11:30
XOMA Royalty Declares Quarterly Preferred Stock Dividends
Barchart · 06/18 06:30
Weekly Report: what happened at XOMA last week (0609-0613)?
Weekly Report · 06/16 11:34
More
Webull provides a variety of real-time XOMA stock news. You can receive the latest news about XOMA Royalty Corporation through multiple platforms. This information may help you make smarter investment decisions.
About XOMA
XOMA Royalty Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's royalty portfolio includes OJEMDA (tovorafenib), Cetrelimab (JNJ-63723283), Ersodetug (RZ358), MIPLYFFATM (arimoclomol), Acimtamig (AFM13), Ficlatuzumab (AV-299), COM902, Vosaroxin, Aldoxorubicin, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, DSUVIA (sufentanil sublingual tablet), IXINITY, Vidutolimod (CMP-001), MT-0169, RZ-402, G03-52-0, AFM24, Mezagitamab (TAK-079), among others. The Company also acquires milestone and royalty revenue streams on late-stage or commercial assets.